PDB16 Prospective and Retrospective Safety Review of Pioglitazone in a Medical Center

Abstract

OBJECTIVES: Diabetes is a serious, costly metabolic disorder with a rising prevalence worldwide. Chromium has long been shown to improve insulin sensitivity, lipid profiles, and blood glucose in insulin resistance and type-2 diabetic patients. METHODS: All relevant databases were searched up to December 2011 limited to human studies in English language. Clinical studies in newly onset patients with type-2 diabetes reporting use of chromium at least for 4 weeks and outcomes of fasting blood glucose (FBG), hemoglobin A1C (HbA1c), triglyceride (TG), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and body mass index (BMI) were identified. Data of before and after use of chromium intake were compared. RESULTS: The functional outcome data from clinical studies revealed that our of 834 studies, 39 met inclusion criteria. Seventy present of articles demonstrated a decrease in FBS while 23% showed an increase. Forty-seven percent of studies showed an increase in HbA1c, while 15% a decrease. TG in 60% of studies showed an increase while in 15% a reduction was reported. LDL cholesterol in 60% of studies showed a decrease and in the rest there was no report of increase. Forty percent of studies showed a decrease in HDL cholesterol while 30% showed an increase. BMI in 40% of studies decreased and in 7% of cases increased. CONCLUSIONS: In clinical studies, average of mentioned parameters were improved significantly after administration of chromium in patients with type 2 diabetes in a dose-dependent manner with no side effects. This systematic review indicates beneficial effects of chromium in diabetic patients.